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Abstract 
Article History 
 
Tamra Bhasma – a generic Ayurvedic mineral formulation was studied for its toxicity in 
laboratory animals. Chronic toxicity was conducted in albino rats (wistar strain). In this study 
Tamra Bhasma was administered orally, daily to different groups of albino rats in TD (Tamra 
Bhasma) and 2 TD (Tamra Bhasma 2 x Therapeutic Doses) doses for 3 months. Tamra 
Bhasma was found to be relatively safe at these dose levels. There was no mortality. No 
significant behavioural changes were noted in any of the group studied. No major alterations 
were observed in haematology, serum biochemical, necropsy and histopathology at the 
administered dose level. The overall chronic toxicity study data indicates that the test 
substance at its TD and 2TD level is very well tolerated since no toxicity symptoms of 
serious cause could be observed in any of the parameters analysed. 
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Introduction 
Bhasma has its unique place in Ayurvedic Therapeutics. 
Bhasmas are basically made from metals and minerals 
[Dhatus and Khanij Dravya]. The process of Bhasmikaran is 
used to transform Dhatus and Khanij into Bhasmas. Synthesis 
of Tamra bhasma involves treating metallic copper with Herbal 
juices and then repeated calcinations in presence of air in 
controlled environment to a form traditionally known as 
‘bhasma’ [1]. Bhasma- an integral part of Ayurveda describes 
about using metals & minerals for chronic disorders in various 
combinations, dosages forms & at various levels of purities. 
Tamra Bhasma which is Ushna, Teekshna & Srotoshodhak 
acts on liver. It induces secretion, circulation of Yakrut Pitta 
(Bile) properly. It is effective in reducing any inflammation or 
edema with its ‘Lekhan’ property. Deficiency of copper in the 
body causes weight loss, bone disorders, microcytic 
hypochromic anaemia, hypopigmentation, graying of hair and 
demyelination of nerves etc [2]. Safety and efficacy depends 
upon the methodology adopted for the preparation and any 
deviation from the classical preparation method will not yield 
desired results. Tamra Bhasma has been in use since long for 
many types of liver and gastro intestinal tract disorders [3]. The 
present study was aimed at screening the drug for its 
safety/toxicity studies in animal model.  
Materials and Methods 
Tamra Bhasma used for study was manufactured by 
Shree Dhootapapeshwar Ltd., Panvel, Navi Mumbai, India. 
The drug was prepared as per classical literature [1]. The test 
substance was dispensed in plastic bags labelled properly and 
was dispatched to an approved Animal House facility 
no.136/1999/CPCSEA, Biomedical Services Unit, Shree 
Dhootapapeshwar Ayurvedic Research Foundation, for 
Toxicity studies without interruption of the custody chain. Test 
substances were coded to blind the identity of the drug.  
A total of 18 Wistar strain albino rats of either sex with 
average body weight 150 to 250 g were obtained from in-
house breeding facility of SDARF. They were maintained in 
ideal laboratory conditions in the prevailing ambient 
temperature (22±02ºC) and humidity (65±05%). The 
experiments were carried out in accordance with the guidelines 
of the Institute’s Animal Ethics Committee after obtaining its 
permission. Dose for experimentation was calculated with 
reference to suggested human doses i.e.60 - 125 mg. For 
toxicity study, higher dose was selected to ascertain its safety 
potential. The animals were divided into three groups (Group-I, 
II and III) containing six rats in each. Group-I rats received 
Tamra Bhasma at a dose equivalent to human therapeutic 
dose (TD- 2.25 mg/200g), Group-II rats received 2 times the 
dose equivalent to human therapeutic dose (2TD- 4.5 mg/200 
g), p.o. for 90 days. Group-III was kept as control. Test drug 
was given as suspension in distilled water by gavage with a 
control group receiving the vehicle (distilled water). Toxicity 
was evaluated by observing the test drug effect on body weight 
and gross behaviour changes, gross and histological 
appearance of vital organs (brain, heart, lungs, liver, spleen, 
kidney and adrenals). Further effect on different biochemical 
variables like total cholesterol, triglycerides, urea nitrogen, 
creatinine, alkaline phosphatase (ALP), total protein,  lactate 
dehydrogenase (LDH), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) and creatinine 
phosphokinase were estimated with the help of an 
autoanalyzer (ERBA CHEM-5, Trans Asia Biomedicals Ltd). 
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Electrolytes Sodium (Na) and Potassium (K) were analysed 
using a flame photometer.  The haematological parameters like 
total white blood cell count (WBC), Total red blood cell count 
(RBC), packed cell volume (PCV), Absolute Erythrocyte 
indices: mean corpuscular volume (MCV), mean corpuscular 
haemoglobin (MCH), mean corpuscular haemoglobin 
concentration (MCHC) and haemoglobin were analysed using 
“Erba hemolab-8 Hematology Analyser”(US Tech Inc, 
Washington, MD, USA). 0.08ml blood was drawn from supra-
orbital plexus of animals and mixed with 0.02ml of EDTA 
(33.33 mg/ml). The sample was fed to auto-analyzer and 
readings were recorded. Differential WBC counts were 
estimated manually.   
The rats were sacrificed by exsanguinations under carbon 
dioxide anaesthesia. Complete necropsies were carried out on 
all animals. Tissues were preserved in 10% neutral buffered 
formalin. The tissues examined were: brain, heart, lungs, liver, 
spleen, kidney, adrenals. Tissues were subjected to 
microscopic examination in this study and were embedded in 
paraffin wax, sectioned at five micrometers and stained with 
haematoxylin and eosin.Organs like Kidneys, liver, adrenals, 
heart, brain, lungs and spleen from all animals were dissected 
free of fat and weighed as soon as possible to avoid drying. 
Values of these organs as percent of necropsy body weights 
were also estimated (relative organ weights). 
Statistical method 
The data were statistically analysed by one way analysis 
of variance. Data are expressed as Mean ±S.D. from 6 rats. P 
value of <0.05 was considered to be statistically significant [4]. 
Specific differences between treatments were examined by the 
Sidak-Bonferroni multiple comparison post hoc test. 
Calculations were made using SPSS (SPSS Inc.1989).   
Results and Discussion 
Hematology 
Values of haemoglobin, hematocrit, total and differential 
leukocyte counts, total erythrocyte counts and erythrocyte 
indices of male and female rats from groups treated with 
Tamra Bhasma (TD) & Tamra Bhasma 2 x Therapeutic Doses 
(2TD) were found to be comparable with those of the control 
group rats (Table 1).  
Clinical Chemistry 
The values of total protein, aspartate aminotransferase, 
alkaline phosphatase, glucose, urea nitrogen, creatinine, 
creatinine phosphokinase, cholesterol, lactate dehydrogenase, 
triglycerides, sodium and potassium of rats treated with Tamra 
Bhasma (TD) and Tamra Bhasma (2TD) were found to be 
comparable with those of the control group rats. The Alanine 
aminotransferase (ALT) value of TD rats was significantly 
lower when compared to control (P< 0.05) but there was no 
significant difference in ALT value of 2TD group with control 
group rats (Table 2). 
All the thirteen Biochemical parameters except ALT 
studied in treatment groups were observed to be in 
consonance with control group. Variation of ALT value 
occurred as remote incidence only in TD group.  Taking these 
values in to account it may be inferred that the results do not 
indicate any serious pathological condition.  
 
Organ Weights 
The absolute & relative values of lungs from all treatment 
groups were found to be lowered as compared to control 
group. Absolute and relative weights of kidneys were found to 
be increased in all treatment groups as compared to control 
group but were not statistically significant at P value of 0.05. 
Significant (P< 0.05) increased relative weights of heart was 
noted in animals treated with Tamra Bhasma (2TD). The 
values of absolute and relative weights of adrenals, brain and 
spleen of male and female rats from treatment groups were 
found to be comparable with those of the control group rats 
(Tables 3 and 4). 
Gross Pathology 
Gross pathological findings noted in rats at necropsy in 
this study included reddening of lungs and small size adrenal 
in TD and Control group. However, these changes occurred as 
isolated incidences and did not appear to be treatment related 
(Table 5).Since no degenerative changes could be observed in 
these organs even in histological examinations, toxicity can be 
ruled out. This happened as isolated incidences in one of the 
TD group and Control group, thus did not appear to be 
treatment related. 
Histopathology 
The microscopic examination of tissues revealed some 
incidental findings, such as acute congestion in liver, kidneys 
and lungs, round cell infiltration in liver and kidneys in the 
treated and control group rats and was considered unrelated to 
exposure to the test article (Table 6). These observations were 
incidental and were considered unrelated to exposure to the 
test substance. Further the microscopic examination of 
Adrenals, Spleen, Brain and Heart showed normal cell 
structure without any sign of degeneration. 
Body Weight 
Body weight gain was observed in control as well as test 
drug administered groups. The body weight gain was slightly 
higher in 2TD group (Table 7). The observed difference was 
found to be statistically non-significant. No significant 
behavioural changes were observed in any of the group 
studied. Body weight change is an important index for 
assessment of toxicity During the study none of the 18 animals 
died. This clearly indicates that it has no serious organ 
degeneration or body function affecting potential. Besides this 
the test drug did not produce any significant changes in the 
cytoarchitecture of any organ studied at various dose levels.  
The overall chronic toxicity study data indicates that the 
test substance at its TD and 2TD level is very well tolerated 
since no toxicity symptoms of serious cause could be observed 
in any of the parameters analysed. The cause for concern is 
the acute congestion and round cell infiltration reported in 
histopathological examination of tissues (liver, kidneys).  The 
fact that these effects observed were not dose dependent in 
nature and occurred in control group also, the result rules out 
serious toxicity potential especially at the dose levels employed 
in therapeutic indications. 
The safety of the drug Tamra bhasma reported may be 
attributed to bhasmikarana process which converts the metal 
into its specially desired chemical compound which eliminates 
the toxicity of the metal and has the necessary medicinal 
benefits [5-6]. 
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Another investigation carried out to study physico-chemical 
changes occurring during bhasma manufacturing indicate that 
the complete process of bhasma preparation (shodhan and 
bhasmikaran) leads to the removal of free copper from the 
system. It begins the synthesis of copper sulphides along with 
some new metallic complexes, which are yet to be characterized 
[7].
  
Table 1:  Summary of Heamatology Data 
Group Hb PCV Total RBC RBC Indices Total WBC Differential WBC (%) 
    MCH MCV MCHC  N L E M 
 (g/dl) (%) (x106/cmm) (pg) (fl) (g/dl) (x103/cmm)     
Tamra Bhasma 
(TD) 
12.15 
+0.49 
37.18+ 
1.25 
7.09 +0.55 17.18 
+0.95 
52.63 
+2.99 
32.70 
+1.08 
8.50  +1.54 27.17 
+4.49 
70.33 
+4.18 
0.67 
+0.82 
1.83 
+0.75 
Tamra Bhasma 
(2TD) 
10.60 
+0.49 
37.08 
+1.10 6.86 +0.43 
15.48 
+1.11 
54.15 
+2.71 
28.62 
+1.93 9.15 +1.12 
26.50 
+5.09 
69.67 
+4.32 
1.33+1.
03 
2.50 
+1.05 
Control 11.60 +0.46 
37.90 
+1.19 7.13 +0.65 
16.35 
+1.44 
53.47 
+4.50 
30.62 
+0.75 8.50 +1.07 
25.00 
+4.05 
71.00 
+4.56 
1.50 
+0.55 
2.50 
+1.38 
Values are expressed as mean +standard deviation (n=6) 
 
Table 2: Summary of Clinical Chemistry Data 
Group Total 
Protein 
ALT AST ALP Glucose UN Cholest Creatinine 
 (g/dl) (IU/L) (IU/L) (IU/L) (mg/dl) (mg/dl) (mg/dl) (mg/dl) 
Tamra Bhasma 
(TD) 6.16 +0.19 
53.04* 
+5.87 120.42+4.90 
118.10+12.9
5 84.38 +2.72 16.37 +0.83 68.40 +4.39 1.01       + 0.07 
Tamra Bhasma 
(2TD) 
6.29 
+0.27 
 
61.42 
+7.61 
 
127.02 
+19.67 
 
127.02 
+17.86 
 
82.23 
+4.28 
 
17.52 
+1.49 
 
73.03 
+9.31 
 
0.94 
+0.05 
 
Control 6.29 +0.26 
65.16 
+4.01 
135.75 
+24.24 
133.78 
+22.61 
86.30 
+7.95 
15.84 
+1.60 
73.68 
+9.58 
0.95 
+0.10 
Values are expressed as mean +standard deviation (n=6) 
* Significantly different from control (P< 0.05) 
Table 2:  (Contd.) 
Group Lactate 
dehydrogenase 
Creatinine 
Phosphokinase 
Triglycerides Sodium Potassium 
 (IU/L) (IU/L) (mg/dl) (mmol/L) (mmol/L) 
Tamra Bhasma 
 (TD) 
541.90 
+125.78 
175.85 
+29.87 
65.98 
+11.80 
147.33 
+9.14 
5.25 
+0.96 
Tamra Bhasma 
(2TD) 
516.82 
+106.66 
193.82 
+28.48 
58.42 
+7.77 
144.83 
+7.41 
5.75 
+0.90 
Control 642.65 +62.36 
191.97 
+18.13 
61.78 
+12.07 
144.33 
+8.02 
5.75 
+1.34 
Values are expressed as mean +standard deviation (n=6) 
Table 3: Summary of Absolute organ weights (g) 
Group Lungs Adrenals Spleen Brain Kidneys Liver Heart 
Tamra Bhasma 
(TD) 
1.62 
+0.38 
0.04 
+0.01 
0.84* 
+0.21 
1.85 
+0.06 
1.96 
+0.50 
9.49 
+2.31 
1.02 
+0.29 
Tamra Bhasma 
(2TD) 
1.25 
+0.14 
0.05 
+0.01 
0.74 
+0.10 
1.82 
+0.12 
1.97 
+0.50 
8.96 
+2.15 
1.03 
+0.21 
Control 1.82 +0.61 
0.05 
+0.01 
0.63 
+0.06 
1.87 
+0.06 
1.70 
+0.44 
8.14 
+1.77 
0.94 
+0.24 
Values are expressed in following sequence: mean, standard deviation (n=6) 
* Significantly different from control (P< 0.05) 
Table 4: Summary of Relative organ weights (% of Body Weights) 
Group Lungs Adrenals Spleen Brain Kidneys Liver Heart 
Tamra  
Bhasma 
(TD) 
0.54 
+0.06 
0.01 
+0.01 
0.28 
+0.06 
0.63 
+0.12 
0.65 
+0.05 
3.15 
+0.36 
62.74 
+11.44 
Tamra  
Bhasma 
(2TD) 
0.43 
+0.12 
0.02 
+0.01 
0.25 
+0.08 
0.62 
+0.14 
0.64 
+0.06 
2.93 
+0.29 
82.56* 
+19.39 
Control 0.62 +0.21 
0.02 
+0.01 
0.22 
+0.05 
0.65 
+0.16 
0.57 
+0.09 
2.73 
+0.42 
54.55 
+14.75 
Values are expressed in following sequence: mean, standard deviation (n=6) 
* Significantly different from control (P< 0.05) 
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  Table 5:  Summary of Necropsy Findings: Incidence 
Group Tamra Bhasma 
(TD) 
Tamra Bhasma 
(2TD) 
Control 
No. of Animals Examined /  No. of animals in the Group 6 /6 6 /6 6 /6 
No abnormality detected 4 / 6 6 /6 4 / 6 
Adrenal (right) - small 1 / 6 - - 
Lungs – moderate reddening 1 / 6 - 2 / 6 
  
  Table 6: Histopathology 
   Summary: Fate: Terminal sacrifice: Incidence of microscopic Findings 
Findings No. of rats with finding / total no. of rats treated 
Group Tamra Bhasma 
(TD) 
Tamra Bhasma 
(2TD) 
Control 
No Abnormality Detected 1 / 6 1 / 6 2 / 6 
Lungs – acute congestion 3/6 3 / 6 3 / 6 
Kidneys – round cells infiltration 1 / 6 - - 
Kidneys – acute congestion 1 / 6 - - 
Liver   – round cells infiltration  3 /6 1/6 2/6 
           - acute congestion 2 / 6 2 / 6 - 
 
Table 7: Body Weights 
 Average body weights of Animals after Chronic Administration of Tamra Basma  
Initial body wt Final body wt 
Control TD 2 TD Control TD 2 TD 
178.33 
+13.29 
178.33 
+ 11.69 
178.33 
+ 11.69 
275.83 
+ 57.82 
275.0 
+ 53.19 
280.83 
+ 61.43 
TD  - Therapeutic Dose 
2 TD  - 2 x Therapeutic Doses 
  
Conclusions 
The test drug is well tolerated since no changes of serious 
nature could be observed in any of the parameters noted 
down. This clearly indicates that the formulation has no serious 
toxicological implications.   
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